Business
Cell MedX Corp: Letter to Shareholders from Mr. Dwayne Yaretz, CEO
Cell MedX Corp: Letter to Shareholders from Mr. Dwayne Yaretz, CEO.
About this update from Stimcell Energetics Inc.
[{"type":"text","content":"Carson City, Nevada--(Newsfile Corp. - June 27, 2022) - Cell MedX Corp. (OTCQB: CMXC) (\"Cell MedX\" or the \"Company\"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to issue the following letter from Mr. Dwayne Yaretz the Company's new CEO.Mr. Yaretz, CEO;Having recently accepted the positions of CEO and Director of Cell MedX, I wanted to introduce myself to you, highlight the Company's most recent accomplishments and our vision for the future. For more than 30 years, I have honed my skills with private and public companies and been instrumental in the development and execution of successful business models that focus and deliver on shareholder value. What drew me to Cell MedX is working within the medical device and electroceutical space to deliver on those same values. I believe in the potential within the bioelectronics and medical device space - an arena that I have had the pleasure of working in firsthand.Back in 2003 at the height of the SARS epidemic, I completed an RTO with Cantronic Systems Inc. to become a publicly trading company and remained as a Director to help them reach their full potential. They needed capital and access to the public markets to accelerate their growth within the medical and industrial device space. Today, Cantronic Systems Inc. supplies its Health Canada approved medical device body temperature scanners to Fortune 500 companies that include Walmart, Johnson and Johnson, Home Depot, Maple Leaf Foods and Saputo as well as Canadian and US government facilities, schools and more than 100 major airports in over 40 countries worldwide. I see that same potential in Cell MedX with their significant progress in the development, testing and approval process in bringing a medical device to market. OPPORTUNITYOur global population is aging, and with aging comes a higher incidence of chronic pain and other ailments. According to the Boston University School of Public Health, \"it is estimated that 1.5 billion people suffer from chronic pain, with prevalence increasing with age.\" This is where I believe the Cell MedX, eBalance® Home and eBalance® Pro System may impact the \"electroceutical/bioelectronics medicine\" marketplace. Time Magazine and Scientific American have reporte...